UK markets close in 32 minutes

Mastercard Incorporated (MA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
352.93-0.45 (-0.13%)
As of 10:58AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close353.38
Open355.85
Bid352.64 x 1800
Ask352.80 x 1100
Day's range351.91 - 355.71
52-week range303.65 - 399.92
Volume703,343
Avg. volume2,897,548
Market cap341.065B
Beta (5Y monthly)1.04
PE ratio (TTM)35.76
EPS (TTM)9.87
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yield1.96 (0.57%)
Ex-dividend date07 Jul 2022
1y target est418.56
  • Editor's pick
    Yahoo Finance Video

    Credit card customers should be 'mindful of ongoing earn' benefits: Analyst

    Krista Phillips, Wells Fargo Credit Cards Head of Branded Cards and Marketing, explains which credit card rewards consumers should be more aware of, ranging from travel expenditures to points for paying for food.

  • Zacks

    5 Stocks With High ROE to Buy on Downtrend in Inflation Data

    Marriott (MAR), Mastercard (MA), Builders FirstSource (BLDR), Rockwell (ROK) and ON Semiconductor (ON) are some of the stocks with high ROE to profit as inflation shows signs of cooling.

  • Motley Fool

    Paysign (PAYS) Q2 2022 Earnings Call Transcript

    This call may include comments that may be deemed to be forward-looking statements under the federal securities laws and the company intends that such forward-looking statements be subject to the safe harbor created thereby. All statements other than statements of fact included on this call are forward-looking statements. Such forward-looking statements include, among others, that our unrestricted cash, anticipated revenues and profits will be sufficient to sustain operations for the next 12 months; that the expected total revenue, gross profit margin, operating expenses, depreciation and amortization, stock-based compensation, adjusted EBITDA, plasma revenues, new plasma center additions, pharma revenues and new pharma co-pay customer additions for 2022 meet our expectations; that the company will continue to post year-over-year improvements; that the company's growth prospects in plasma, pharma and other prepaid business materialize; and that the company will continue to be affected by COVID-19-related labor shortages.